

# Update of the scientific evidence on asbestos and cancer

Kurt Straif, MD MPH PhD

International Agency for Research on Cancer  
Lyon, France

World Health Organisation

Asturias, 17 March 2011



## The IARC Monographs

### Consensus evaluations


of the weight of the evidence that an agent can increase the risk of cancer in humans

Approximately 900 agents evaluated since 1971

|   |     |
|---|-----|
| 1 - <i>carcinogenic to humans</i>           | 110 |
| 2A - <i>probably carcinogenic to humans</i> | 64  |
| 2B - <i>possibly carcinogenic to humans</i> | 243 |

National and international health agencies use the *Monographs*

- As a source of information to identify potential carcinogens
- As scientific support for their actions to prevent cancer



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer



## IARC Monographs, Volume 100 *A Review of Human Carcinogens*

- **Scope of volume 100**
  - Update the critical review for each carcinogen in Group 1
  - **Identify tumour sites and plausible mechanisms**
  - Compile information for subsequent scientific publications
- **The volume was developed over the course of 6 meetings**
  - A. *Pharmaceuticals* (23 agents, Oct 2008)
  - B. *Biological agents* (11 agents, Feb 2009)
  - C. *Metals, particles and fibres* (14 agents, Mar 2009)
  - D. *Radiation* (14 agents, June 2009)
  - E. *Lifestyle factors* (11 agents, Sept 2009)
  - F. *Chemicals and related occupations* (34 agents, Oct 2009)



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer



### Special Report: Policy

#### A review of human carcinogens—Part C: metals, arsenic, dusts, and fibres

| Group 1 agent   | Tumour sites (or types) for which there is sufficient evidence in humans | Other sites with limited evidence in humans | Established mechanistic events   |
|---|--|---|--|
| Arsenic and inorganic arsenic compounds   | Lung, skin, urinary bladder  | Kidney, liver, prostate                     | Oxidative DNA damage, genomic instability, aneuploidy, gene amplification, epigenetic effects, DNA-repair inhibition leading to mutagenesis  |
| Beryllium and beryllium compounds   | Lung   | --  | Chromosome aberrations, aneuploidy, DNA damage   |
| Cadmium and cadmium compounds   | Lung   | Prostate, kidney                            | DNA-repair inhibition, disturbance of tumour-suppressor proteins leading to genomic instability  |
| Chromium (VI) compounds   | Lung   | Nasal cavity and paranasal sinuses          | Direct DNA damage after intracellular reduction to Cr(III), mutation, genomic instability, aneuploidy, cell transformation   |
| Nickel compounds  | Lung, nasal cavity, and paranasal sinuses                                | --  | DNA damage, chromosome aberrations, genomic instability, micronuclei, DNA-repair inhibition, alteration of DNA methylation, histone modification   |
| Asbestos (chrysotile, crocidolite, amosite, tremolite, actinolite, and anthophyllite) | Lung, mesothelioma, larynx, ovary  | Colorectum, pharynx, stomach                | Impaired fibre clearance leading to macrophage activation, inflammation, generation of reactive oxygen and nitrogen species, tissue injury, genotoxicity, aneuploidy and polyploidy, epigenetic alteration, activation of signalling pathways, resistance to apoptosis |
| Erionite  | Mesothelioma   | --  | Genotoxicity   |
| Silica dust, crystalline in the form of quartz or cristobalite                        | Lung   | --  | Impaired particle clearance leading to macrophage activation and persistent inflammation   |
| Leather dust  | Nasal cavity and paranasal sinuses                                       | --  | --   |
| Wood dust   | Nasal cavity and paranasal sinuses, nasopharynx                          | --  | --   |

Table: Metals, arsenic, dusts, and fibres assessed by the IARC Monograph Working Group




International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer

Straif et al, Lancet Oncol, 2009



## IARC Monographs on Asbestos



## IARC Monographs on Asbestos

Actinolite, amosite, anthophyllite, chrysotile, crocidolite, tremolite

- Vol 2, 1973: sufficient evidence in humans, sufficient evidence in animals (1)
- Vol 14, 1977: sufficient evidence in humans, sufficient evidence in animals (1)
- Suppl 7, 1987: sufficient evidence in humans, sufficient evidence in animals, 1

<http://monographs.iarc.fr/>



## Asbestos: Mesothelioma and lung cancer, V100C


- The epidemiologic evidence has only strengthened over time and there is currently overwhelming evidence that **all commercial forms of asbestos fibers are causally associated** with an increased risk of **mesothelioma and lung cancer**.
- There are still current **controversies** about the extent to which there are **potency** differences for the particular **forms** of asbestos (i.e. chrysotile versus amphiboles) and **sizes** (i.e. long and thin fibers). However, these issues do not alter the fundamental conclusion that the epidemiologic evidence indicates that **all forms and sizes of commercial asbestos fibers are carcinogenic to humans**.



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer



## Exposure to asbestos and mesothelioma mortality in UK



Adapted from Hodgson et al, 2005



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer



## Asbestos: open questions

- **Lung cancer potency varies by fiber type?**  
pro review by Hodgson & Darton 2000 (10x),  
con review by Stayner et al. 1996
- **Lung cancer potency varies by fiber size?**  
indirect epidemiologic evidence (textile industry)  
supports belief that fibers > 10  $\mu\text{m}$  have higher  
carcinogenic potency for lung cancer
- **Mesothelioma potency varies by fiber type?**  
chrysotile < amphiboles, amosite may be < crocidolite,  
but: mesothelioma among Chinese workers exposed to  
“pure” chrysotile (Yano 2001)
- **Mesothelioma potency varies by fiber size?**  
pro: mesothelioma at South Carolina > Quebec miners  
con: South Carolina textile < New Orleans cement plant



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer



## Chrysotile and cancer – recent epidemiological evidence

- Cohort of 5782 workers of 4 textile plants in NC, USA, followed-up 1950-2003. Lung cancer SMR 2.0 (95%CI 1.7-2.2), mesothelioma SMR 11.1 (95%CI 3.0-28.4); RR increased with time since first employment and duration of employment (Loomis et al, 2007)
- Cluster of 14 mesothelioma cases among workers who were active in the Balangero mine, Italy, and 13 among other people exposed to Balangero chrysotile adds further evidence to the carcinogenicity of tremolite-free chrysotile (Mirabelli et al, 2008).
- Cohort of 3072 workers of 1 textile plant in SC, USA, followed-up 1940-2001. Lung cancer was most strongly associated with exposure to thin (< 0.25  $\mu\text{m}$ ) and longer (> 10  $\mu\text{m}$ ) fibers (TEM) (Stayner et al, 2008)



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer




## Asbestos: Laryngeal cancer, V100C

- Fairly **consistent findings** of both the occupational cohort studies as well as the case-control studies, plus the evidence for **positive exposure-response relationships** between cumulative asbestos exposure and laryngeal cancer that is reported in several the well conducted cohort studies.
- Meta-analyses of 29 cohort studies** encompassing 35 populations and of **15 case-control studies** of asbestos exposure and laryngeal cancer undertaken by the Institute of Medicine (2006).
- There is **sufficient evidence** to infer a **causal relationship between asbestos exposure and laryngeal cancer**.




## Asbestos and Ovarian Cancer



NOTE: Weights are from random effects analysis




## Asbestos: colorectal cancer, V100C



RR of colorectal cancer among people in highest exposure category compared to non-exposed



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer



## Asbestos: mechanistic data, V100C

- The mechanistic basis for asbestos carcinogenicity is a **complex interaction** between these crystalline mineral fibres and target cells in vivo.
- The most important **physicochemical properties of asbestos fibres** related to pathogenicity are **surface chemistry and reactivity, surface area, fibre dimensions, and biopersistence**.
- **Multiple direct and indirect mechanisms** have been proposed based on numerous in-vitro cellular assays and acute and subchronic animal bioassays. These complex mechanisms most likely **interact at multiple stages during the development of lung cancer and diffuse malignant mesothelioma**.



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer



## Asbestos: mechanistic data, V100C

### Species differences

- There are **significant species differences** in the responses of the respiratory tract to inhalation of asbestos fibres.
- The **biological mechanisms** responsible for these species differences are **unknown**.
- Based on comparative animal experimental studies, there may be **differences in deposition and clearance of fibres in the lungs, in severity of fibrosis, in kinetics of translocation of fibres to the pleura, and in levels or types of antioxidant defence mechanisms.**



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer



## Asbestos: Overall evaluations, V100C

- There is *sufficient* evidence in humans for the carcinogenicity of all forms of asbestos (chrysotile, crocidolite, amosite, tremolite, actinolite and anthophyllite). **All forms of asbestos cause mesothelioma and cancers of the lung, larynx and ovary.**
- The Working Group classified the evidence for **colorectal cancer** as *limited* although the Members were evenly divided as to whether the evidence was strong enough to warrant classification as *sufficient*.
- There is *limited* evidence in humans for cancers of the **pharynx** and of the **stomach**.



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer



## Burden of asbestos-related cancer

Recently, several new global and national estimates of attributable fractions (AF) for occupational cancer have been published

- Nurminen & Karjalainen, Finland (2001);
- Steenland et al, USA (2003);
- Driscoll et al, WHO GBD (2005);
- Rushton et al, UK (2008)

Used **different methods to estimate asbestos-related lung cancer** (based on mesothelioma mortality and mesothelioma/lung cancer ratio estimate; Levin's or Miettinen's equation)



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer



## UK Burden of Occupational Cancer


All IARC Group 1 and 2A carcinogens with "strong" or "suggestive" evidence for specific site in humans (Siemiatycki et al, 2004)

| Cancer Site    | AF (%)      |             |             | Deaths (2005) |             |             | Registrations (2004) |             |              |
|----------------|-------------|-------------|-------------|---------------|-------------|-------------|----------------------|-------------|--------------|
|                | M           | F           | Total       | M             | F           | Total       | M                    | F           | Total        |
| Mesothelioma   | 97.0        | 82.5        | 95.0        | 1699          | 238         | 1937        | 1699                 | 238         | 1937         |
| Sinonasal      | 46.0        | 20.1        | 34.4        | 29            | 10          | 40          | 102                  | 32          | 134          |
| Lung           | 22.2        | 5.5         | 15.2        | 4236          | 757         | 4993        | 4877                 | 850         | 5727         |
| Nasopharynx    | 11.1        | 2.5         | 8.3         | 7             | 1           | 8           | 16                   | 1           | 17           |
| Bladder        | 7.2         | 1.9         | 5.4         | 218           | 31          | 248         | 503                  | 55          | 558          |
| Breast         |             | 4.6         | 4.6         |               | 555         | 555         |                      | 1971        | 1971         |
| NMSC           | 7.0         | 1.2         | 4.6         | 20            | 2           | 23          | 2542                 | 387         | 2909         |
| Larynx         | 2.9         | 1.8         | 2.6         | 18            | 3           | 20          | 51                   | 6           | 56           |
| Oesophagus     | 3.3         | 1.1         | 2.5         | 157           | 28          | 185         | 160                  | 29          | 189          |
| STS            | 3.4         | 1.1         | 2.3         | 12            | 4           | 16          | 25                   | 6           | 30           |
| Stomach        | 3.0         | 0.3         | 2.0         | 102           | 6           | 108         | 150                  | 9           | 159          |
| NHL            | 2.1         | 1.1         | 1.7         | 49            | 23          | 71          | 110                  | 51          | 161          |
| Melanoma (eye) | 2.9         | 0.4         | 1.8         | 1             | 0           | 1           | 6                    | 1           | 7            |
| <b>Total</b>   | <b>8.45</b> | <b>2.35</b> | <b>5.51</b> | <b>6588</b>   | <b>1702</b> | <b>8290</b> | <b>10406</b>         | <b>3703</b> | <b>14109</b> |



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer

Rushton et al, Occ Env Med; 2008.



## Burden of asbestos-related cancer

85-90% of male **mesothelioma** cases due to occupational asbestos exposure

Among men, 17-29% of all **lung cancer** due to occupational exposure

**Lung cancer** accounted for 54-75% of occupational cancer

**Asbestos** accounted for ca. 50% of occupational lung cancer.

Straif, Occ Env Med, 2008



International Agency for Research on Cancer  
Centre International de Recherche sur le Cancer

